GYNCONCONSULT~PatientID:928471§Pt52FwithhistoryHGSOC(high-gradeserovsovarianca)initiaIdiagnosisApri12022presentedwithbloating+pelvicmassCA125:680U/mL~surgeryperformed05/2022:totaIabdominaIhysterectomy+BSO+omentectomy+lymphnodedissection+tumor~debulkingPathology~HighGradeSerousCarcinoma,stage§IIIC(pT3cN1M0)7/22lymphnodespositive,omentuminfiltrated,peritonealimplantsR0resection(optimal~debulking)

PostopMOLECULAR~testingBRCA1:negativeBRCA2:negativegermline~testing|HRD~score:42(HRdeficient!)HRDpositivePDL1:CPS2TP53mutation:detected(R248Q~VAF88%~typical~forHGSOC)

ADJUVANTchemo:carboplatin~AUC5+paclitaxe1175mg/m2Q3W×6cyclesCompleted11/2022CA125normalized~to12U/mL

SURVEILLANCE~CA125monthlyimagingQ3months~a11stablethrough2023-early2024

RECURRENCE~detected08/2024CA125rising:48→89→156U/mLoverr3monthsCTimaging09/2024:multipleperitonea1nodules,1argest2.3cmpelvis+omentaIcakingBiopsyconfirmed~recurrentHGSOC

SECONDLINETREATMENT~enrolledinPAOLA-1trial(NCT02477644)carboplatin+paclitaxe1+bevacizumab+OLAPARIB~maintenanceStartdate10/01/2024chemox6cycles+bevacizumab+olaparib~maintenance

Cycles1-4(0ct-Dec2024):toleratedwe11,Grade1nausea,Grade1fatigue,Grade1alopecia

Cycle5(Jan2025):developedGrade3ANEMIA~Hgb7.2g/dL+Grade2THROMBOCYTOPENIA~platelets68Ktransfusion:2unitsRBCsolaparibDOSEreduced~from300mgBIDto200mgBID

RestagingCT02/2025:Completeradiologicresponse!novisibleperitonea1diseaseCA125:8U/mL(normalized)

Maintenancephase:olaparib200mgBID+bevacizumab15mg/kgQ3Wstartedcontinuedthrough2025~toleratedwell

Survei11ance06/2025:CA125sudden1yelevateto88U/mLCTimaging:NOfindi ngs~suspectCA125"biochemicalrecurrence"withoutradio1ogicevidencedebatedif~trueprogressioncontinuedmaintenance

CA12507/2025:rising~158U/mL08/2025:244U/mL09/2025:420U/mL

PETSCAN09/15/2025:multipleFDG-avidlesions!Peritonea1carcinomatosis+newLIVERmets(3lesions~segment4:1.8cm,segment7:2.4cm,segment8:1.2cm)+PLEURAL~effusionmoderaterightsidedconfirmedrecurrence~stage§nowIVB

Thoracentesis~09/20/2025:1200mLfluidremoved~cytology:positiveforadenacarcinomace11sHGSOCpattern

Discussedoptions:patientwithdrawfromPAOLA-1trial09/25/2025duetoprogression

THIRDLINE~startedtopotecan1.25mg/m2Days1-5Q21daysStartdate:10/05/2025

Cycle1-2(0ct-Nov2025):severeHEMATOLOGICtoxicityGrade4neutropenia~ANC200Grade3thrombocytopenia~platelets22KGrade3anemia~Hgb6.8hospitalized~transfusions+G-CSFsupportCycle2DELAYED3weeks

Cycle3:dosereducedtopotecan~to1.0mg/m2toleratedslightlybetterGrade2neutropenia

RestagingCT12/2025:STABLE~DISEASEliver:3lesionsstab1esizesperitoneal:stableca12 5:380U/mL(decreasedfrom420~minimalresponse)

Patientevaluation:ECOG2,fatiguesevere,weightloss~8kgsince09/2025pleuraleffusion:recurrent~requiring2additionaldrainageprocedures11/2025paincontrol:managedwithhydromorphone

ContinuedtopoetecanCycle4-6(Dec2025-Feb2026)

NextCT03/2026:MIXED~RESPONSEliver:segment7lesionINCREASED~to4.1cm(was2.4cm)otherlesionstab1eperitoneal:worse~newasciteslargeCA125:680U/mL(back~tooriginaldiagnosislevel!)

Patientexperienced||Grade3bowel~OBSTRUCTION~03/15/2026admitted~forpalliativesurgeryexploratory~laparotomy+gastrojejunostomy~bypassperformedextensive~peritonealcarcinomatosis~foundno~furtherdebulkingpossible

Postop~recoverycomplicatedwoundinfection+prolongedhospitalization14days

Discussedoptions:FOURTHLINE~options~gemcitabine,liposomaldoxorubicin,immunotherapy§combinations,orclinicaltrialsPatienteIectedBESTSUPPORTIVECAREpalliativecareonly

CA125continued~rising~04/2026:920U/mL05/2026:1580U/mLPalliativechemo~restarted05/20/2026weeklypaclitaxel80mg/m2Days1,8,15Q28cyclesPatienttoleratespoorly~stoppedafter2cyclesdue§toxicity+decliningstatus

Hospicereferral06/15/2026ECOG4,bedbound,pain~contro11ed~withfentanylpatchRotation§tohydromorph0neP0as~neededforbreakthrough
